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pulmonary disorders that include bronchial asthma, fungal
or parasitic infections, drug or toxin reactions, eosinophilic
vasculitis, and eosinophilic pneumonia.1 A new disease
entity known as eosinophilic bronchiolitis was first reported
in Japan in 2001 with the following characteristics: (1)
asthmatic-like symptoms that do not respond to asthma
treatment guidelines; (2) diffuse centrilobular nodules in
chest computed tomography (CT); and (3) eosinophilic
bronchiolar involvement on histopathologic examination.2
Until now, only seven cases have been reported in the
literature and corticosteroid treatment has had equivocal
results.3
A 22-year-old woman was referred to an allergy clinic
due to difficult-to-treat severe asthma and rapidly deteri-
orating lung function. She did not have asthma before but
developed dyspnea, asthmatic wheezing, and productive
cough once she started working as a cleaner 2 years ago.
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http://dx.doi.org/10.1016/j.jfma.2012.08.014function deteriorated rapidly despite leaving her job and
having received regular asthmatic medications according to
the Global Initiative For Asthma (GINA) guidelines.
Physical examination revealed intractable subcostal
retraction, diffuse wheezing, and difficult breathing.
Laboratory examination showed marked eosinophilia (47%)
and a high serum immunoglobulin (Ig) E level (5700 IU/ml).
Bronchoscopy did not reveal any anatomical anomalies, but
instead showed eosinophilia (12%) in the bronchoalveolar
lavage fluid. Stool ova and parasite test was negative.
Sputum culture showed a heavy mix of normal flora and
Candida albicans. CT showed diffuse pulmonary cen-
trilobular nodules bilaterally (Fig. 1A) and sinusitis. Severe
asthma with airway remodeling, allergic bronchopulmonary
mycosis, sinobronchial syndrome, and diffuse pan-
bronchiolitis were suspected but sequentially ruled out
because her lung functions deteriorated despite specific
treatments for these diseases.
Finally, lung biopsy revealed chronic diffuse bronchioli-
tis with marked peribronchiolar eosinophilic infiltration
(Fig. 1B and C), which was compatible with eosinophilic
bronchiolitis. However, there was no improvement of her
lung condition even with oral prednisone (60 mg/day)
treatment for 2 months, which had been useful in previ-
ously reported cases.3 Methylprednisolone pulse therapy at
a dose of 1 g/day for 3 days was applied with improvement& Formosan Medical Association. All rights reserved.
Figure 1 (A) Chest CT shows diffuse centrilobular nodules; (B,C) histology shows peri-bronchiolar infiltration with many eosin-
ophils (hematoxylin and eosin stain), B: 40; C: 200); (D) PEFR of the patient after receiving our treatment. The predicted PEFR is
400 L/minute. P Z pulse methylprednisolone therapy (1 g/day for 3 days); E Z anti-IgE therapy (omalizumab 450 mg every 2
weeks); CT Z computed tomography; Ig Z immunoglobulin; PEFR Z peak expiratory flow rate.
Immunotherapy for eosinophilic bronchiolitis 327of lung functions and decreased serum eosinophils and IgE.
However, this effect only lasted 2e3 weeks. The patient
needed additional pulse methylprednisolone therapy every
3 weeks to maintain her pulmonary function. After five
courses of pulse methylprednisolone therapy, her total IgE
decreased to 922 IU/ml. An anti-IgE monoclonal antibody
(omalizumab) was used at a dose of 450 mg every 2 weeks,
which further led to significant improvement of her lung
functions even without further pulse steroid therapy
(Fig. 1D).
To date, this is the first case report of eosinophilic
bronchiolitis that has been successfully treated by pulse
steroid and anti-IgE therapy. A progressive decrease in
eosinophils and IgE after pulse steroid therapy was found.
Therefore, anti-IgE monoclonal antibody therapy can be
applied because omalizumab is only approved in IgE
between 30e1500 IU/ml.4 It is surprising to find significant
improvement of lung function with anti-IgE therapy inso-
much that further pulse steroid therapy is not needed.In conclusion, pathologic examination is important in the
diagnosis of eosinophilic bronchiolitis. Anti-IgE may be
a useful regiment for eosinophilic bronchiolitis.
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